Santosha Vardhana, a physician-scientist at Memorial Sloan Kettering, sums up the problem in a sentence most oncologists will recognize: “A tragic part of T cell exhaustion is that the immunotherapy seems to be working for patients, and then it fades.” The T cells that were clearing the tumor stop clearing it, and the field calls them “exhausted,” a word that suggests a soldier slumped against a wall.
Telling a soldier to shoot less so it lives longer is a plausible bargain in that corner of the clinic.
Tanmana Mitra, first author on the lab’s new paper in Immunity, found that the slumped soldier was really a sprinter who had run out of fuel. Exhausted T cells, the team reported, were metabolically busy, burning energy and turning out cancer-killing protein until they had nothing left. “We realized T cell exhaustion isn’t simply a loss of function,” Mitra said. In the institution’s account, exhaustion reflects an imbalance between what these cells are being asked to do and the energy they have. That leads to the strangest proposal in the work: to keep a cancer-fighting cell alive longer, make it fight less hard.
The dial, according to the paper, is a signaling molecule called MEK. Under constant stimulation from tumor antigen, MEK drives the cell to step up protein synthesis across the board. The demand for ATP climbs, NADH piles up in the mitochondria, and the mitochondria start to fail. Block MEK and the cell spends less and lasts longer in the harsh tumor environment, though it also hits the tumor less hard in the meantime. Vardhana’s version: “MEK tells exhausted cells whether to conserve fuel or go for broke.” The Sloan Kettering write-up adds that exhaustion may be partly protective, “almost like a ‘safe mode’ for T cells,” which makes the decision to override it more delicate than the headline suggests.
Then the pitch begins. MEK inhibitors aren’t years away from a first human trial. They are FDA-approved and already on pharmacy shelves, and ScienceDaily’s summary of the work notes that MEK inhibition has already shown effectiveness in melanoma when combined with checkpoint inhibitors and a BRAF inhibitor. “FDA-approved MEK inhibitors are already available,” Vardhana said, “so this approach could be tested in humans without much delay.” From there the press materials list the modern immunotherapies that could benefit: checkpoint inhibitors, CAR T cells, tumor-infiltrating lymphocyte therapy and bispecific antibodies.
In the lab and animal models, the throttled T cells lasted longer. Nobody yet knows whether patients would. Neither Sloan Kettering’s announcement nor the ScienceDaily write-up reports a survival curve, a tumor-shrinkage percentage or a sample size, so a reader has nothing to measure the effect against what checkpoint therapy already delivers. That isn’t a knock on the immunology, since basic science is supposed to work this way. It’s a measure of the distance between a signaling result and the phrase “without much delay,” and many mechanisms that looked tidy in a dish have been lost crossing it.
The trade cuts both ways, and to their credit the researchers say so. “But when it comes to cancer patients, one size doesn’t fit all,” Vardhana said. Patients with small tumors and plenty of immune cells already attacking them, often because their tumors carry many mutations, probably don’t need MEK inhibition. For them, in Vardhana’s analogy, “It’s like being in a car with 1/8 of a tank left, but you can see the finish line.” By the lab’s own account, the case is strongest for patients with large tumors or few tumor-reactive cells, whose immune response may not clear the cancer quickly. Telling a soldier to shoot less so it lives longer is a plausible bargain in that corner of the clinic. It is also the kind of bargain that looks clean in a lab model and gets complicated in a person whose cancer won’t wait while the immune system paces itself.
The money behind the work is the ordinary federal and foundation kind: an NCI career-development award, a Burroughs Wellcome Fund career award, a V Foundation scholarship, Sloan Kettering’s Josie Robertson Investigators program, the institution’s NCI Cancer Center Support Grant and an internal pre-doctoral fellowship, all listed in the Sloan Kettering announcement. The disclosure line below it is shorter. Vardhana has consulted for Generate:Biomedicines and has received research funding from Bristol Myers Squibb, unrelated to this work. Bristol Myers Squibb sells nivolumab, marketed as Opdivo, a PD-1 immune checkpoint inhibitor, which puts the company in the very drug class this finding is pitched to make work longer. Nothing on the record suggests the funding shaped the science, and the disclosure is doing what disclosure is for. It still means that the scientist proposing an approved drug class as a booster for checkpoint immunotherapy has taken research money from a company that sells a checkpoint drug, and readers are entitled to keep that in mind while hearing the pitch.
Exhaustion as an energy budget rather than a broken switch is an elegant idea, and if it holds up in human trials it would change how the field thinks about keeping engineered T cells in the fight. For now it rests on one Immunity paper, a set of lab and animal models, and a drug cabinet that happens to be already stocked. Memorial Sloan Kettering put the word “could” in the headline of its July announcement, and for once the hedge is exactly the right size.
Sources
- Memorial Sloan Kettering Cancer Center: New Strategy Could Prevent T Cell Exhaustion and Boost Immunotherapy
- Immunity: MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion (Mitra, Rahman, Hwee, et al., 2026)
- ScienceDaily: Cancer-fighting T cells burn out. Scientists may have found a fix
- Healio: FDA approves Opdivo for advanced, treatment-naive BRAF wild-type melanoma